

Nippon Shinyaku: Leading Products

(¥ million)

	2014	2015	2016	2017	2018	2019	2020 (estimated)
Net Sales	79,991	84,209	98,781	101,448	114,716	116,637	126,000
Operating profit	8,562	8,549	15,280	17,079	20,644	21,668	25,000
Ordinary Profit	8,928	8,952	16,244	17,451	21,540	22,442	25,500
Profit attributable to owners of parent	5,882	6,340	11,749	12,953	16,302	16,866	19,000

May 13, 2020

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2018	Sales 2019	Sales 2020 (estimated)	
						Apr.-Sep.	Annual
Vidaza	azacitidine	myelodysplastic syndrome	Mar-11	14,453	15,652	8,100	16,800
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-14	12,118	13,328	5,000	8,400
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-10	7,196	7,153	3,600	7,400
Uptravi	selexipag	pulmonary arterial hypertension	Nov-16	4,825	6,182	3,700	7,900
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-09	5,173	5,405	2,800	5,600
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-18	1,417	4,527	2,700	5,600
Cialis	tadalafil	erectile dysfunction	Jul-09	4,592	4,472	1,700	3,200
Erizas	dexamethasone cipeclate	allergic rhinitis	Dec-09	2,987	2,387	750	2,500
Azunol Gargle	sodium gualenate	pharyngitis, tonsillitis, stomatitis, etc.	Aug-02	2,169	2,159	950	2,100
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-19	-	1,071	1,000	2,200
Profit in co-promotion				5,057	5,963	3,950	8,300
Revenues from the licensing of industrial				16,621	15,860	8,900	19,700
Pharmaceuticals				100,223	101,643	52,100	110,700
Functional Food				14,492	14,994	7,400	15,300
Net Sales				114,716	116,637	59,500	126,000